Pharmacological treatment of stable angina pectoris: the place of trimetazidine

According to international epidemiological studies, the total number of reported cases cardiovascular diseases (CVD) almost doubled from 1990 2019, reaching 523 million and deaths CVD in 2019 increased by more than 1.5 times (18,6 million). Coronary artery disease (CAD) stroke are main contributors these unfavorable trends. The registered coronary heart amounted 197 million, caused exceeded half all death (9,14 Patients with stable angina majority patients CAD. Despite existing modern methods treating pectoris, chronic continue suffer anginal pain, which significantly reduces exercise tolerance worsens their quality life. In clinical practice, severity frequency pectoris remain underestimated doctors, drug therapy is not corrected a timely manner, possibilities combined antianginal used. Trimetazidine, as an that acts on metabolism ischemic myocardial cells (influence cascade, reducing cellular acidosis increasing ATP content), effective safety for treatment regardless mechanism ischemia monotherapy combination, primarily beta-blockers.